PARTNERSHIPS THAT CHANGE THE STATUS QUO

Unitaid’s investments build highways for better health products to travel from the minds of innovators to people all over the world. But we cannot succeed in isolation. We collaborate with many types of partners—governments, industry, international and civil society organizations—to make sure innovations are quickly scaled up into life-changing solutions for everyone who needs them. Global health presents enormous challenges, and demands an intelligent and sustainable response from us. Each new investment takes us one step closer to fulfilling our collective vision of a fairer, healthier world.
UNITAID IN NUMBERS

US$ 1.3 BILLION PORTFOLIO VALUE

GRANTS FROM 28 TO 48

FROM 2014 TO TODAY
More than 60% investments focusing on antimicrobial resistance

More than 60 new products supported

127 grant implementers
UNITAID: A UNIQUE POSITION IN THE GLOBAL HEALTH RESPONSE

UNITAID acts as a bridge between innovators and the partners that carry health solutions far and wide.

SAVING LIVES WITH INNOVATION

Unitaid improves the lives of the most vulnerable with better medicines, tests and prevention methods—products that are more effective and tolerable, better adapted to people’s needs, and less prone to resistance.
SOLUTIONS FOR MILLIONS

Unitaid works with a range of partners to make sure these quality products are widely available and affordable for countries.
ENHANCING HEALTH SYSTEMS

We address major global health needs through integrated approaches. We go beyond HIV, tuberculosis and malaria, investing in other areas such as cervical cancer and hepatitis C.
SCALE-UP: THE MEASURE OF OUR SUCCESS

Our investments bring innovations to countries in record time, opening avenues for governments and partners to introduce them on a large scale.
BETTER PRODUCTS, HEALTHIER LIVES

WE FIND THE BEST IDEAS AND TURN THEM INTO PRACTICAL SOLUTIONS FOR MILLIONS OF PEOPLE.
BRINGING BETTER HIV TREATMENTS IN RECORD TIME

IMPACT

5 million more people could access treatment thanks to lower prices

94 countries can access DTG through voluntary licensing

Dolutegravir (DTG) suppresses the virus more quickly and is less prone to drug resistance

DTG has fewer side effects

Reaching target price of US$ 55 per person per year will contribute to further scalability

US$ 87 million investments in optimizing HIV treatments

Unitaid and partners have brought new, affordable HIV medicines to people in Africa in only three years, three times faster than for previous generations of antiretrovirals. Further reductions in prices will save the global health response US$ 300 million each year.
Unitaid and partners have revolutionized childhood TB treatment with quality paediatric medicines that are affordable and taste good. Unitaid is also investing in better approaches to help find the one million children affected by TB each year, and to identify drug-resistant strains.
The ACCESS-SMC project demonstrated that the delivery of SMC during the rainy season in the Sahel is feasible and cost-effective. Twelve countries, up from seven, are now delivering SMC.
Malaria-carrying mosquitoes have become resistant to certain insecticides and are changing their biting habits, threatening the gains in malaria control. Unitaid and its partners are finding new ways to manage and mitigate resistance with the first long-lasting insecticides recommended by WHO in 40 years, new bed nets, anti-parasitic drugs, and treated plastic sheets that drive mosquitoes away from where people live.
HIV self-testing is a convenient way for people to find out their status, especially where stigma is high. It is also the first step to accessing prevention and treatment services. Unitaid and partners have succeeded in introducing quality-assured, affordable self-testing kits across Africa in only three years. Fifty-nine countries now have policies on HIV self-testing.
Better treatment for severe malaria in children

A lifesaving emergency treatment for children with severe malaria, known as rectal artesunate, is prequalified by the World Health Organization (WHO). This enables procurement and distribution by international funders. The treatment is manufactured by Cipla Ltd. and supported by Unitaid and the Medicines for Malaria Venture.

HIV: cutting the price of 3 in 1 pill

Unitaid seals a landmark deal with Cipla Ltd. to slash the price of Q-TIB, which prevents opportunistic infections in people living with HIV. The HIV virus can weaken the immune system, increasing the risk of life-threatening infections by bacteria, fungi and viruses. Under this agreement, Cipla will reduce the ceiling price of the medicine by more than 30 percent.
New initiative for malaria elimination in Asia Pacific
Unitaid and the Asia Pacific Leaders Malaria Alliance (APLMA) launch a collaborative Vector Control Platform for Asia Pacific (VCAP). It brings together key actors in the region to accelerate access to innovations against malaria. The objective is to boost access to innovations against malaria and other mosquito-borne diseases in the region.

New investments: revolution in HIV diagnosis
Unitaid invests US$26 million in two projects led by the MTV Staying Alive Foundation and Solthis to further scale up HIV self-testing in Africa. These investments build on the strong evidence provided by Unitaid-funded initiatives. Results show that self-test kits are a cost-effective way to reach undiagnosed populations and high-risk groups.

New investment: MenStar Coalition
Unitaid and a diverse group of partners jointly launch the MenStar Coalition, an effort to expand the diagnosis and treatment of HIV in men, particularly in sub-Saharan Africa. The MenStar Coalition is launched at the International AIDS Society Conference (AIDS 2018) under the auspices of Unitaid, the Elton John AIDS Foundation (EJAF), PEPFAR, the Global Fund and the Children’s Investment Fund Foundation (CIFF).

Moving to the Global Health Campus
Unitaid moves to the Global Health Campus alongside the Global Fund, Gavi the Vaccine Alliance, the RBM Partnership to End Malaria and the Stop TB Partnership, strengthening its cooperation with key partners.
New investment: fighting resistance with new bed nets
Unitaid and the Global Fund jointly invest US$ 66 million into the New Nets project, to be led by the Innovative Vector Control Consortium (IVCC). The initiative pilots new-generation insecticide-treated bed nets to fight insecticide resistance in countries hardest hit by malaria.

UNGA: speeding up innovation to end TB
Unitaid is invited to speak at the United Nations General Assembly’s (UNGA) High-Level Meeting on tuberculosis, where it highlights the urgent need to speed up innovation to end TB.

Joining forces to advance the health SDGs
Eleven heads of the world’s leading health and development organizations, including Unitaid, sign a landmark commitment to find new ways of working together to advance the UN Sustainable Development Goals (SDGs).
New investment: preventing deaths from advanced HIV
Unitaid invests US$ 20 million to avert deaths from advanced HIV disease. The grant, to be implemented by Clinton Health Access Initiative (CHAI), is designed to make new tests and treatments affordable and available in lower-income countries.

New investment: promoting HIV self-testing in Kenya
Unitaid invests US$ 1.5 million to stimulate HIV self-testing in Kenya in partnership with the Elton John AIDS Foundation (EJAF) and the Children’s Investment Fund Foundation (CIFF).

Funding boost from the United Kingdom
The United Kingdom provides an additional £27 million to Unitaid to invest in malaria control, building upon its existing investment as a founding member of Unitaid.

New investments: innovative malaria vector control
Unitaid invests US$ 59 million in two innovative projects to corner malaria-carrying mosquitoes. These projects will be led by the University of Notre Dame and the Barcelona Institute for Global Health (ISGlobal).

New investment: screen & treat for cervical cancer
Unitaid is investing US$ 33 million to speed up access to screen-and-treat solutions for as little as US$ 1. The initiative, to be led by CHAI, will deploy artificial intelligence-based screening tools and will introduce new portable devices for treatment of precancerous cervical lesions. Cervical cancer kills a woman every two minutes and disproportionately affects low-resource countries and women living with HIV.
THE SECRETARIAT

89 PEOPLE

33 NATIONALITIES

38% MEN 62% WOMEN
Unitaid’s current main funders are France, the United Kingdom, Brazil, Norway, Chile, the Republic of Korea, Spain and the Bill & Melinda Gates Foundation.
UNITAID’S LEAD GRANTEES

FOR MORE INFORMATION ON UNITAID’S PROJECTS AND PARTNERS, VISIT UNITAID’S WEBSITE.